Abstract | AIMS: MATERIALS AND METHODS: One hundered twenty patients (with a solitary HCC<or=7.0 cm in diameter or multiple HCC (<or=3), each <or=3.0 cm in diameter) treated with PRFA combined with TACE were compared with 120 well-matched controls selected from a pool of 652 patients who received PRFA alone during the study period. RESULTS: The 1-, 2-, 3-, 5-year overall survival rates for the TACE-PRFA and PRFA groups were 93%, 83%, 75%, 50%, and 89%, 76%, 64%, 42%, respectively (p=.045). Subgroup analyses showed the survival for the TACE-PRFA group was better than the PRFA group for tumors >5.0 cm (p=.031) and for multiple tumors (p=.032), but not for tumors <or=5.0 cm (p=.319) and for solitary tumor (p=.128). The 1-, 2-, 3-, 5-year progression free survival (PFS) for the TACE-PRFA and PRFA groups was 90%, 76%, 63%, 42%, and 76%, 60%, 47%, 30%, respectively (p=.002). Child-pugh class, Diameter of tumor and hepatitis B surface antigen ( HBsAg) were significant prognostic factors. CONCLUSION: Patients treated with TACE-PRFA had better overall survivals than PRFA alone, but only in a subgroup of patients with tumor >5 cm or multiple tumors.
|
Authors | Z-W Peng, M-S Chen, H-H Liang, H-J Gao, Y-J Zhang, J-Q Li, Y-Q Zhang, W Y Lau |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 36
Issue 3
Pg. 257-63
(Mar 2010)
ISSN: 1532-2157 [Electronic] England |
PMID | 19643561
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright (c) 2009 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Antineoplastic Agents
(administration & dosage)
- Carcinoma, Hepatocellular
(mortality, pathology, therapy)
- Catheter Ablation
(methods)
- Catheterization
- Chemoembolization, Therapeutic
(methods)
- China
(epidemiology)
- Female
- Follow-Up Studies
- Humans
- Injections, Intra-Arterial
- Liver Neoplasms
(mortality, pathology, therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Retrospective Studies
- Survival Rate
(trends)
- Treatment Outcome
|